BioCentury
ARTICLE | Company News

Allergan, Senju deal

May 31, 2004 7:00 AM UTC

AGN granted Senju an exclusive license to develop and market Lumigan bimatoprost ophthalmic solution - 0.03%. Senju is responsible for the development and commercialization of Lumigan in Japan and wi...